摘要
目的 :观察中药圣和散联合肝动脉介入对消化道肿瘤肝转移的疗效。方法 :5 4例消化道肿瘤肝转移患者随机分成两组 ,治疗组 2 8例采用圣和散联合介入化疗 ,对照组 2 6例采用单纯介入化疗。结果 :近期有效率治疗组为 46.43 % ,对照组为3 0 .77% ,两组比较有显著性差异 (P<0 .0 5 )。治疗组 0 .5 ,1,2 ,3年生存率分别为 92 .86% ,71.43 % ,46.43 %和 2 8.5 7% ,明显优于对照组的 84.62 % ,61.5 4% ,2 6.92 %和 11.5 4% (P <0 .0 5 )。治疗组平均生存期 2 3 .4个月 ,优于对照组的 16.4个月 (P <0 .0 5 )。同时发现治疗组能明显改善临床症状 ,调节细胞免疫功能和降低 AF P,无明显毒副作用。结论 :圣和散联合介入治疗能明显提高消化道肿瘤肝转移患者生活质量 。
Objective: To explore the therapeutic ef fects of transcatheter hepatic arterial chemoembolization (TACE) plus Shenghe po wder for patients with liver metastases from digestive tract cancer. Methods: 54 patients with unresectable liver metastases from digestiv e tract cancer were randomized to two groups. Treated group of 28 cases were tre ated with TACE plus Shenghe powder, controled group of 26 cases were treated wit h TACE alone. Results: The short-term effective rate (CR+ PR) was 46.43% in treated group and 30.77% in controled group (P<0.05). The 0.5-, 1-, 2-, 3-year survival rate in treated group was 92.86%, 71.43%, 46. 43% and 28.57% respectively, significantly higher than that of 84.62%, 61.54%, 2 6.92% and 11.54% in controled group (P<0.05). The mean survival period in t wo groups was 23.4 months and 16.4 months respectively, the differences were sta tistically significant (P<0.05). Meanwhile the treated group could effectiv ely ameliorate the clinical symptoms, improve hepatic functions, lower AFP. No o bvious side effect was found. Conclusion: Shenghe powder p lus TACE could improve the survival quality and prolonging the survival time to patients with metastastic cancer of the liver.
出处
《时珍国医国药》
CAS
CSCD
2001年第8期F003-F003,F004,共2页
Lishizhen Medicine and Materia Medica Research
基金
山西省科委科技攻关项目 (No.0 0 2 0 59
关键词
转移性
化学栓塞
治疗
圣和散
消化道肿瘤
Liver cancer
Secondary/therapy
Chemoe mbolization
Shenghe powder
